MA33984B1 - Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique - Google Patents

Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique

Info

Publication number
MA33984B1
MA33984B1 MA35118A MA35118A MA33984B1 MA 33984 B1 MA33984 B1 MA 33984B1 MA 35118 A MA35118 A MA 35118A MA 35118 A MA35118 A MA 35118A MA 33984 B1 MA33984 B1 MA 33984B1
Authority
MA
Morocco
Prior art keywords
sgc
combination
cystic fibrosis
treatment
pde5 inhibitors
Prior art date
Application number
MA35118A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Sandner
Degenfeld Georges Von
Johannes-Peter Stasch
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33984(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA33984B1 publication Critical patent/MA33984B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)

Abstract

La présente invention concerne une guanylate cyclase soluble (sgc) et les phosphodiestérases (pde) et la pharmacologie des stimulateurs de sgc, activateurs de sgc et inhibiteurs de pde. Plus particulièrement, l'invention concerne l'utilisation de stimulateurs de sgc et d'activateurs de sgc en combinaison avec des inhibiteurs de pde5 pour la préparation de médicaments pour le traitement de la fibrose kystique (cf).
MA35118A 2010-02-05 2011-02-03 Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique MA33984B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10152727 2010-02-05
PCT/EP2011/051532 WO2011095534A1 (fr) 2010-02-05 2011-02-03 Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique

Publications (1)

Publication Number Publication Date
MA33984B1 true MA33984B1 (fr) 2013-02-01

Family

ID=43759663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35118A MA33984B1 (fr) 2010-02-05 2011-02-03 Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique

Country Status (33)

Country Link
US (1) US20130035340A1 (fr)
EP (1) EP2531187B1 (fr)
JP (2) JP6143461B2 (fr)
KR (1) KR101793304B1 (fr)
CN (3) CN107929271A (fr)
AU (1) AU2011212521B2 (fr)
BR (1) BR112012019666A2 (fr)
CA (1) CA2788969C (fr)
CL (1) CL2012002173A1 (fr)
CR (1) CR20120408A (fr)
CY (1) CY1116878T1 (fr)
DK (1) DK2531187T3 (fr)
EA (1) EA025177B1 (fr)
ES (1) ES2548394T3 (fr)
HK (1) HK1212892A1 (fr)
HR (1) HRP20151187T1 (fr)
HU (1) HUE028008T2 (fr)
IL (1) IL221012B (fr)
MA (1) MA33984B1 (fr)
MX (1) MX342944B (fr)
MY (2) MY159697A (fr)
NZ (1) NZ601612A (fr)
PH (1) PH12012501587A1 (fr)
PL (1) PL2531187T3 (fr)
PT (1) PT2531187E (fr)
RS (1) RS54336B1 (fr)
SG (1) SG182819A1 (fr)
SI (1) SI2531187T1 (fr)
SM (1) SMT201500286B (fr)
TN (1) TN2012000397A1 (fr)
UA (1) UA112962C2 (fr)
WO (1) WO2011095534A1 (fr)
ZA (1) ZA201205532B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011212521B2 (en) * 2010-02-05 2015-11-19 Adverio Pharma Gmbh sGC stimulators or sGC activators alone and in combination with PDE5 inhbitors for the treatment of Cystic Fibrosis
AU2011257336B2 (en) 2010-05-26 2015-11-19 Adverio Pharma Gmbh The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc).
US20130158028A1 (en) * 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EP2594270A3 (fr) * 2011-11-18 2013-07-31 BIP Patents Utilisation de stimulateurs de la sGC ou d'activateurs de la sGC, seuls et en combinaison avec des inhibiteurs de PDE5 pour le traitement de la sclérose systémique (Ssc)
SG10201510668UA (en) * 2012-09-07 2016-01-28 Boehringer Ingelheim Int Alkoxy pyrazoles as soluble guanylate cyclase activators
US10265314B2 (en) * 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
WO2015089105A1 (fr) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
US20160311826A1 (en) 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
AP2016009615A0 (en) 2014-07-22 2016-12-31 Boehringer Ingelheim Int Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
MX2017003518A (es) 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
HK1254636A1 (zh) 2015-12-18 2019-07-26 Novartis Ag 作为可溶性鸟苷酸环化酶激活剂的茚满衍生物及其用途
AU2017378324B2 (en) * 2016-12-16 2021-09-02 Cystic Fibrosis Foundation Bycyclic heteroaryl derivatives as CFTR potentiators
CN110305125B (zh) * 2019-06-06 2021-09-03 山东新华制药股份有限公司 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
PL199236B1 (pl) * 1998-07-08 2008-08-29 Sanofi Aventis Deutschland N-Aryloamidy kwasów sulfonyloaminokarboksylowych podstawionych siarką, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie N-aryloamidów kwasów sulfonyloaminokarboksylowych podstawionych siarką
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005047946A1 (de) * 2005-10-06 2007-05-03 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
RU2009145935A (ru) * 2007-05-12 2011-06-20 Байер Шеринг Фарма Акциенгезельшафт (DE) Стимуляторы ргц, активаторы ргц и комбинации для лечения урологических нарушений
CN101939053A (zh) * 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
WO2009068652A1 (fr) 2007-11-30 2009-06-04 Smithkline Beecham Corporation Pyridines 2, 6-disubstituées et pyrimidines 2, 4-disubstituées en tant qu'activateurs de guanylate cyclase soluble
PE20091258A1 (es) 2007-12-03 2009-09-12 Smithkline Beecham Corp Derivados de piridina como activadores de la guanilato ciclasa soluble
US8461348B2 (en) * 2008-04-04 2013-06-11 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
ES2559840T3 (es) * 2008-06-04 2016-02-16 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2011212521B2 (en) * 2010-02-05 2015-11-19 Adverio Pharma Gmbh sGC stimulators or sGC activators alone and in combination with PDE5 inhbitors for the treatment of Cystic Fibrosis

Also Published As

Publication number Publication date
PT2531187E (pt) 2015-10-20
IL221012A0 (en) 2012-09-24
CL2012002173A1 (es) 2013-05-17
SI2531187T1 (sl) 2016-01-29
EA201290702A1 (ru) 2013-02-28
US20130035340A1 (en) 2013-02-07
JP6143461B2 (ja) 2017-06-07
MX2012009011A (es) 2012-09-07
SG182819A1 (en) 2012-09-27
ZA201205532B (en) 2014-12-23
SMT201500286B (it) 2016-01-08
CN107929271A (zh) 2018-04-20
CA2788969A1 (fr) 2011-08-11
KR20120125276A (ko) 2012-11-14
WO2011095534A1 (fr) 2011-08-11
TN2012000397A1 (en) 2014-01-30
JP6270907B2 (ja) 2018-01-31
PL2531187T3 (pl) 2016-01-29
MY159697A (en) 2017-01-13
AU2011212521B2 (en) 2015-11-19
RS54336B1 (sr) 2016-02-29
AU2011212521A1 (en) 2012-08-16
MY160856A (en) 2017-03-31
HRP20151187T1 (hr) 2015-12-04
BR112012019666A2 (pt) 2017-06-20
CY1116878T1 (el) 2017-04-05
JP2016155857A (ja) 2016-09-01
HK1212892A1 (zh) 2016-06-24
UA112962C2 (uk) 2016-11-25
EP2531187B1 (fr) 2015-08-12
HUE028008T2 (en) 2016-11-28
JP2013518851A (ja) 2013-05-23
PH12012501587A1 (en) 2020-10-19
CN104800219A (zh) 2015-07-29
EA025177B1 (ru) 2016-11-30
DK2531187T3 (en) 2015-11-09
EP2531187A1 (fr) 2012-12-12
MX342944B (es) 2016-10-18
IL221012B (en) 2018-01-31
CA2788969C (fr) 2017-11-21
CR20120408A (es) 2013-02-12
ES2548394T3 (es) 2015-10-16
CN102770133A (zh) 2012-11-07
KR101793304B1 (ko) 2017-11-02
NZ601612A (en) 2014-08-29

Similar Documents

Publication Publication Date Title
MA33984B1 (fr) Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique
EA201170942A1 (ru) СТИМУЛЯТОРЫ рГЦ ИЛИ АКТИВАТОРЫ рГЦ В КОМБИНАЦИИ С ИНГИБИТОРАМИ ФДЭ5 ДЛЯ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ
MX2022002581A (es) Compuestos de benzimidazol como inhibidores de c-kit.
EA201291309A1 (ru) ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОДНИХ И В КОМБИНАЦИИ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc)
EA201491371A1 (ru) Соединение пиразинкарбоксамида
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MY172021A (en) Rsv antiviral compounds
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
EA201791284A1 (ru) Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака
CL2012003048A1 (es) Compuestos derivados de n-fenil-3-(1h-pirazol-4-il)quinoxalin-6-amina, inhibidores de tirosino quinasa fgfr; proceso de preparación; composición farmacéutica; y su uso en la prevención o tratamiento de cáncer.
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
PH12014500103A1 (en) Pyridin-2(1h)-one derivatives as jak inhibitors
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
WO2012064667A3 (fr) Traitement d'addiction et de troubles de contrôle des impulsions au moyen d'inhibiteurs de la pde7
MX2014014468A (es) Compuestos triazolo como inhibidores de fosfodiesterasa 10 (pde10).
PH12016502353A1 (en) Pharmaceutical composition
MA40583A (fr) Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation
NZ741785A (en) 3-cyano-1h-1,2,4-triazol-1-yl compounds and uses thereof for the treatment of hiv
MX2014015271A (es) Inhibidor de jak1 y jak2.
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
MX2012008438A (es) Procedimientos de preparacion de dispersiones acuosas basadas en poliuretano-ureas.
UA110933C2 (uk) Композиція для лікування есенціальної тромбоцитемії
PH12012502198A1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof